Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. More>

We’re expanding our gene pool Genzyme is a diversified enterprise of over 10,000 employees globally, many of whom have helped us introduce a diverse range of life-saving breakthrough medical treatments. The company’s products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease. Innovation and commitment are key to our success and our dedicated teams are at the heart of our enterprise. More> Search for job opportunities at Genzyme

Watch a video featuring employees from Genzyme Ireland Genzyme Ireland Team Members talk about the company and their work. Watch>.

Terms and Conditions of Use | Privacy Policy | © 2002-2013 Genzyme Ireland Ltd., a Sanofi company. All rights reserved.